CCL2 and diabetic kidney disease: Additionally, SGLT2i have been shown to inhibit monocyte chemoattractant protein-1 (MCP-1) gene expression, blocking an important factor leading to inflammation, fibrosis, and tubular atrophy in DKD [143,144,145].